What is a generic name, and how does the WHO assign one to a drug?
Every pharmaceutical compound receives an International Nonproprietary Name (INN) from the World Health Organization before it is approved or marketed. The INN is the molecule’s official scientific identity — it does not belong to any company, it does not expire, and it is the same in every country. When doctors, pharmacists, researchers, and regulators discuss the molecule, they use the INN.
Brand names, by contrast, are commercial identities assigned by the manufacturer. They can differ by country, by indication, or by formulation. The INN is stable across all of those variations.
For tirzepatide, the INN was assigned to describe a specific synthetic peptide: a dual agonist at two receptors, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). That dual-agonism is what distinguishes tirzepatide from earlier GLP-1-only compounds like semaglutide.
Brand names versus tirzepatide generic name
Eli Lilly markets tirzepatide under two brand names in the United States:
- Mounjaro — approved by the FDA for glycemic control in adults with type 2 diabetes (an FDA-approved indication).
- Zepbound — approved by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (an FDA-approved indication).
Both products contain tirzepatide at the same concentrations (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per pen). The active molecule is chemically identical; what differs is the approved indication and the brand packaging.
Compounded tirzepatide is neither Mounjaro nor Zepbound. It is the generic molecule — tirzepatide — prepared by a licensed 503A compounding pharmacy for a specific patient under a clinician’s prescription. Compounded medications are not FDA-approved, but they can be legally dispensed under 503A compounding rules when appropriate conditions are met.
The generic name is the molecule’s permanent scientific identity — one name that outlasts every brand, country, and indication.
Why does the tirzepatide generic name matter for patients seeking access or compounding?
The confusion between brand names and generic names has real consequences for patients trying to understand their options:
- Insurance coverage: Insurance plans typically specify coverage by brand name. Compounded tirzepatide is generally not covered because it is not the FDA-approved branded product. Understanding the distinction sets realistic expectations about out-of-pocket costs.
- Compounding access: When a patient asks a telehealth clinician about tirzepatide, they are asking about the generic molecule. Whether they receive it as Zepbound (if FDA-approved access is available) or as a compounded preparation depends on the clinical pathway and what the pharmacy dispenses under the prescription.
- Research interpretation: Clinical trial publications cite the generic name tirzepatide, not the brand names. Knowing this helps patients find and evaluate the actual published evidence on the compound they are taking.
- Regulatory status: FDA statements about tirzepatide shortage status, compounding permissions, and safety communications use the generic INN, not the brand names. Tracking these developments requires familiarity with the generic name.
What “dual GIP/GLP-1 agonist” means in plain terms
The pharmacological description of tirzepatide — a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — is dense but unpacks simply:
- GLP-1 receptor agonism reduces appetite, slows gastric emptying (how quickly food leaves the stomach), and improves insulin secretion in response to meals. GLP-1-only compounds like semaglutide work through this receptor.
- GIP receptor agonism adds a complementary layer: it affects fat metabolism and may amplify the appetite-suppression effect when combined with GLP-1 signaling. The GIP component is what distinguishes tirzepatide mechanistically from earlier GLP-1-only drugs.
The dual mechanism is why SURMOUNT-1 and subsequent tirzepatide trials reported weight loss outcomes that compared favorably to semaglutide trials — though direct head-to-head data between the two molecules at equivalent doses is limited.
Compounded tirzepatide: same molecule, different source
Licensed 503A compounding pharmacies may prepare tirzepatide for individual patients under specific conditions. The active ingredient is the same generic molecule — the same tirzepatide INN — but the product:
- Is compounded for a specific patient rather than mass-manufactured
- Is not FDA-approved (compounding operates under a different regulatory framework)
- May use additives like bacteriostatic water and is presented in multi-dose vials rather than pre-filled autoinjector pens
- Is dispensed only with a valid prescription from a licensed clinician
PepScribe works only with licensed 503A compounding pharmacies in the United States. Every dispensed product is compounded domestically. There is no hidden overseas supply chain.
Frequently asked questions
What is the generic name of tirzepatide?
Tirzepatide is itself the International Nonproprietary Name (INN) — the generic name. The brand names are Mounjaro (for blood sugar management in type 2 diabetes, an FDA-approved indication) and Zepbound (for chronic weight management, an FDA-approved indication). Compounded tirzepatide uses the same generic INN but is prepared by a licensed 503A compounding pharmacy and is not FDA-approved.
Is tirzepatide the same as Mounjaro or Zepbound?
Tirzepatide is the active molecule in both Mounjaro and Zepbound. Those are brand names for the FDA-approved versions manufactured by Eli Lilly. Compounded tirzepatide is the same peptide molecule prepared by a licensed 503A compounding pharmacy rather than a pharmaceutical manufacturer.
What does the name tirzepatide mean?
The INN follows a naming stem convention. The "-tide" suffix signals a peptide-based therapeutic. The "tirze-" prefix is a coined root specific to this molecule. The full name is assigned by the WHO INN Programme to uniquely identify the active substance across all countries and all brand names.
Is compounded tirzepatide FDA-approved?
Compounded tirzepatide is not FDA-approved. Compounded medications are prepared by licensed pharmacies for specific patients and are not subject to the same pre-market approval process as branded drugs. FDA approval applies only to Mounjaro and Zepbound, the manufactured Eli Lilly products.
Why do patients search for the generic name of tirzepatide?
Most patients start their search with a brand name they saw in an ad or heard from a friend. When they learn the molecule has a generic name — tirzepatide — they realize it can be discussed independently of the brand, which matters for understanding compounding options, pricing, and clinical literature.